To further investigate the impact of VASH2 on pancreatic cancer sensitivity to gemcitabine in vivo we analyzed the tumor control rate using a xenograft model of subcutaneous tumor growth in nude mice. Here, VASH2 is linked to pancreatic neoplasm.